Skip to content

Study · Randomized controlled trial · 2023

5 results

Effects of Aerobic Training and Semaglutide Treatment on Pancreatic β-Cell Secretory Function in Patients With Type 2 Diabetes.

Ingersen A, Schmücker M, Alexandersen C, Graungaard B, Thorngreen T, Borch J, Holst JJ, Helge JW, Dela F

The Journal of clinical endocrinology and metabolism1 Oct 2023Cited by 28 (Europe PMC)

PMID37265222 (opens in a new tab)DOI10.1210/clinem/dgad326 (opens in a new tab)PepBankPUB-37265222
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, the median increase in total insulin secretion with semaglutide plus training was 134 nM x 2 hours greater than with training alone.

    In plain wordsIn patients with type 2 diabetes, adding semaglutide to exercise training raised insulin release more than training alone.

    Peptide
    Semaglutide
    Outcome
    IncreaseTotal insulin secretion increase, semaglutide plus training versus training alone
    Study

    n: not reported in source

    Comparator
    Aerobic training alone
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Median difference in total insulin secretion
    134 nM x 2 hours
    combination vs training

    Source sentences

    Summary
    The median increase in total insulin secretion with the combination was 134 nM × 2 hours greater (95% CI 108-232) than with training.
    2 context sentences
    Summary · context
    Thirty-one patients with type 2 diabetes underwent 12 weeks of aerobic training alone or concurrent to treatment with semaglutide.
    Summary · context
    Patients randomly allocated to concurrent semaglutide and training were treated with semaglutide for 20 weeks before the training and evaluated at inclusion and again before and after the training intervention.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, 20 weeks of semaglutide increased insulin secretion during clamp step 1 from 16 to 111 nM x 2 hours (ratio 7.10).

    In plain wordsIn patients with type 2 diabetes, 20 weeks of semaglutide raised the body's insulin release during a glucose clamp test.

    Peptide
    Semaglutide
    Outcome
    IncreaseIncremental insulin AUC during hyperglycemic clamp step 1
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 20 weeksAs given in this study (human).

    Measurements

    Insulin AUC before
    16 nM x 2 hours
    step 1
    Insulin AUC after
    111 nM x 2 hours
    step 1
    Ratio
    7.1
    step 1

    Source sentences

    Summary
    Semaglutide treatment increased insulin secretion from 16 to 111 nM × 2 hours (ratio 7.10, 95% CI 3.68-13.71), and from 35 to 447 nM × 2 hours (ratio 12.74, 95% CI 5.65-28.71), correspondingly.
    2 context sentences
    Summary · context
    Thirty-one patients with type 2 diabetes underwent 12 weeks of aerobic training alone or concurrent to treatment with semaglutide.
    Summary · context
    Patients randomly allocated to concurrent semaglutide and training were treated with semaglutide for 20 weeks before the training and evaluated at inclusion and again before and after the training intervention.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, 20 weeks of semaglutide increased insulin secretion during clamp step 2 from 35 to 447 nM x 2 hours (ratio 12.74).

    In plain wordsIn patients with type 2 diabetes, 20 weeks of semaglutide raised the body's insulin release at a higher glucose level.

    Peptide
    Semaglutide
    Outcome
    IncreaseIncremental insulin AUC during hyperglycemic clamp step 2
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 20 weeksAs given in this study (human).

    Measurements

    Insulin AUC before
    35 nM x 2 hours
    step 2
    Insulin AUC after
    447 nM x 2 hours
    step 2
    Ratio
    12.74
    step 2

    Source sentences

    Summary
    Semaglutide treatment increased insulin secretion from 16 to 111 nM × 2 hours (ratio 7.10, 95% CI 3.68-13.71), and from 35 to 447 nM × 2 hours (ratio 12.74, 95% CI 5.65-28.71), correspondingly.
    2 context sentences
    Summary · context
    Thirty-one patients with type 2 diabetes underwent 12 weeks of aerobic training alone or concurrent to treatment with semaglutide.
    Summary · context
    Patients randomly allocated to concurrent semaglutide and training were treated with semaglutide for 20 weeks before the training and evaluated at inclusion and again before and after the training intervention.

Studies that did not test the peptide alone2

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 04HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, semaglutide combined with aerobic training increased insulin secretion during clamp step 1 from 130 to 171 nM x 2 hours (ratio 1.31).

    In plain wordsIn patients with type 2 diabetes, semaglutide together with exercise training raised insulin release during a glucose clamp test.

    Peptide
    Semaglutide
    Outcome
    IncreaseInsulin secretion with semaglutide plus training, clamp step 1
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Insulin AUC before
    130 nM x 2 hours
    step 1
    Insulin AUC after
    171 nM x 2 hours
    step 1
    Ratio
    1.31
    step 1

    Source sentences

    Summary
    Semaglutide and training increased insulin secretion from 130 to 171 nM × 2 hours (ratio 1.31, 95% CI 1.06-1.63), and from 525 to 697 nM × 2 hours (ratio 1.33, 95% CI 1.02-1.72), correspondingly.
    2 context sentences
    Summary · context
    Thirty-one patients with type 2 diabetes underwent 12 weeks of aerobic training alone or concurrent to treatment with semaglutide.
    Summary · context
    Patients randomly allocated to concurrent semaglutide and training were treated with semaglutide for 20 weeks before the training and evaluated at inclusion and again before and after the training intervention.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 05HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, semaglutide combined with aerobic training increased insulin secretion during clamp step 2 from 525 to 697 nM x 2 hours (ratio 1.33).

    In plain wordsIn patients with type 2 diabetes, semaglutide together with exercise training raised insulin release at a higher glucose level.

    Peptide
    Semaglutide
    Outcome
    IncreaseInsulin secretion with semaglutide plus training, clamp step 2
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Insulin AUC before
    525 nM x 2 hours
    step 2
    Insulin AUC after
    697 nM x 2 hours
    step 2
    Ratio
    1.33
    step 2

    Source sentences

    Summary
    Semaglutide and training increased insulin secretion from 130 to 171 nM × 2 hours (ratio 1.31, 95% CI 1.06-1.63), and from 525 to 697 nM × 2 hours (ratio 1.33, 95% CI 1.02-1.72), correspondingly.
    2 context sentences
    Summary · context
    Thirty-one patients with type 2 diabetes underwent 12 weeks of aerobic training alone or concurrent to treatment with semaglutide.
    Summary · context
    Patients randomly allocated to concurrent semaglutide and training were treated with semaglutide for 20 weeks before the training and evaluated at inclusion and again before and after the training intervention.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT04383197

Exercise and GLP-1 RA on Insulin Secretion

University of Copenhagenn = 3010 Dec 2019 to est. Aug 2022

Type 2 Diabetes

Trial pageClinicalTrials.govUpdated 11 Feb 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.